monoclonal antibody, in the cell membrane of a human assayed.
colon carcinoma growing in cell culture (SWI 116) and AFP concentrations were measured in (Koprowski et al., 1981; Magnani et al., 1982; 1983) . Raised sera which had been obtained by peripheral venesection, serum values of the antigen have been found in patients with separated and frozen within 2 h, and stored at -20°C. In the a variety of gastrointestinal tumours, particularly pancreatic case of the cancer patients, serum was obtained for assay carcinoma, in which a sensitivity for CA of 70% or before cancer chemotherapy was begun. CA 19-9 values were more has consistently been reported (Koprowski et al., 1981;  measured by solid-phase sandwich radioimmunoassay Del Villano et al., 1983; Kuusela et al., 1984; Jalanko et al., 1984; Satake et al., 1985; Gupta et al., 1985 ; Schmiegel Thirty-seven u ml-I was therefore used as the upper limit of et al., 1985) . In addition, CA 19-9 is detectable histonormal in the present study.
chemically in the corresponding tissues (Atkinson et al., 1982) . Low concentrations of the antigen are present in the HCC Patients Raised CA 19-9 concentrations were present serum of healthy individuals (Koprowski et al., 1981 (20-(Atkinson et al., 1982) . The possibility that this antigen 500ngml-1), so that 70.2% (85/121) of the patients had a might be expressed by hepatocellular carcinoma (HCC) diagnostic AFP value (>500 ng ml-1). therefore arises. In fact, raised serum values have been Of the 18 patients with a normal serum AFP described in ten of 36 patients with this tumour, and also in concentration, 12 had an elevated CA 19-9 value. Thus, if four of 27 patients with benign hepatic diseases (Jalanko et the two tumour markers were used together only 5% of al., 1984; Satake et al., 1985; Andriulli et al., 1986) . The patients (6/121) would have elevation of neither marker. Of purpose of this study was to measure serum concentrations the 18 patients with a non-diagnostic AFP value, 7 had a of CA 19-9 in a larger series of patients with HCC and in raised CA 19-9 value. Thus, 9% (11/121) of HCC patients more patients with those forms of benign hepatic disease would have an equivocal AFP value and a negative CA 19-9 which might be mistaken clinically for HCC, and to compare test. the sensitivity, specificity and predictive value of CA 19-9 with alpha-foetoprotein (AFP), a proven serum marker of Benign hepatic diseases Serum CA 19-9 values were raised this tumour (Kew, 1974) .
in 29.4% (15/51) of the patients with benign hepatic diseases.
One hundred and twenty one southern African Blacks Four patients (7.8%) had a value of 37-50uml-1, 5 (9.8%) with histologically-proved HCC were included in the study.
51-100uml-1, and 7 (13.7%) >100uml-1. The results in There were 110 men and 11 women; their ages ranged from the patients with amoebic hepatic abscess were: raised 25% 18 to 82 years (mean 43.8 years). Twenty eight patients with (7/28), 37-50uml-1 10.7% (3/28), 51-100uml-1 7.1% an amoebic hepatic abscess, 23 with chronic hepatic (2/28), > 100 u mP1 10.7% (3/28), and in those with chronic parenchymal disease (chronic active hepatitis, cryptogenic hepatic parenchymal disease: raised 34.8% (8/23), 37-cirrhosis, alcoholic cirrhosis) and 26 with a wide variety of SOuml-' 4.3% (1/23), 51-100 13.0% (3/23), > lOOumP' malignant tumours other than HCC (arising from lung, 17.4% (4/23). colon, stomach, oesophagus, prostate, adrenal, cervix, ovary, Serum AFP concentrations were increased in 8 of the 51 breast, thyroid, kidney; melanoma) were also studied. All of patients (15.7%) with benign hepatic diseases. The two these patients were Blacks.
patients with an abscess (7.1%) who had a raised value had The normal range of CA 19-9 in serum (<37 uml1) has levels of 25 and 54 ngml 1, respectively. 9 and AFP are compared in Table I . If a cut-off level for Other tumours Raised concentrations of CA 19-9 were found in 10 of the 26 patients (38.5%) with other tumours (3 with carcinoma of the cervix, 3 with ovarian carcinoma, one each with carcinoma of the breast, thyroid, and kidney, and one with a germinoma). Three patients (11.5%) had values of 37-50uml-1, 4 (15.4%) 51-lOuml-1, and 3 (11.5%) > 100 um-1. Small numbers of patients with HCC were included in three previous analyses of serum concentrations of CA 19-9 in malignant and inflammatory gastrointestinal diseases (Jalanko et al., 1984; Satake et al., 1985; Andriulli et al., 1986) . Raised values were recorded in one of four patients studied by Satake et al. (1985) and in five of 14 patients studied by Andriulli et al. (1986) . Jalanko and his colleagues (1984) found increased concentrations in four of 18 patients (22%) with HCC, but also in four of 27 with benign hepatic diseases. The present investigation has shown elevated CA 19-9 values to be present appreciably more often in southern African Blacks with HCC. Although this level of sensitivity as a marker is less than that described in carcinoma of the pancreas, it is comparable with that obtained with other gastro-intestinal carcinomas (Koprowski et al., 1981; Del Villano et al., 1983; Kuusela et al., 1984; Jalanko et al., 1984; Satake et al., 1985; Gupta et al., 1985; Schmiegel et al., 1985) . The specificity of CA 19-9 in differentiating HCC from various benign hepatic diseases with which it might be confused clinically was 71%, with a predictive value of a positive test of 80.5% and of a negative test of 39.9%. While these results show CA 19-9 to be a more useful serum marker of HCC than was suggested by the earlier data, comparison with AFP shows the latter to be far more useful in the diagnosis of this tumour.
If the two markers are used together in the diagnosis of HCC, the number of patients without a raised serum AFP concentration could be reduced from 15% to 5% and the number with an equivocal AFP value from 15% to 9%. If a diagnostic cut-off point for AFP of 500ngml-1 is used, a sensitivity of 70% is still obtained in southern African Blacks with HCC and the specificity and predictive values of positive and negative tests increase to 100%. The question whether the specificity and predictive value of CA 19-9 could similarly be improved by using a diagnostic cut-off level of 100uml-1 was addressed. At this level, the sensitivity decreases to 33% while the increase in specificity and the predictive value of a positive test do not reach statistical significance; the predictive value of a negative test remains low (35%).
Indirect confirmation of our finding and that of previous workers that CA 19-9 is frequently not expressed by HCC is provided by the observation of Atkinson et al. (1982) that only one of 11 HCCs examined with immunoperoxidase staining was positive for CA 19-9. Our finding of raised serum concentrations of CA 19-9 in patients with a variety of non-gastrointestinal tumours confirms the observation of Gupta et al. (1985) that CA 19-9 is not specific for gastrointestinal tumours.
In support of the observation of Jalanko et al. (1984) , we too found elevated serum concentrations of CA 19-9 in patients with inflammatory disease of the liver. The reason why this antigen is expressed in inflammatory diseases of the liver (acute and chronic hepatic parenchymal disease and amoebic hepatic abscesses) is not known. Other tumourrelated antigens, such as tissue polypeptide antigen, may also be found in high concentration in the serum of patients with inflammatory hepatic disease (Kew & Berger, 1986) . One possible explanation for these findings is that these antigens can be expressed by regenerating hepatocytes as well as by malignant hepatocytes.
